Roche's Hemlibra Priced And Labeled To Beat Competition, Safety Concern

Genentech/Roche's Hemlibra, now FDA-approved for hemophilia A patients with inhibitors, offers a once-weekly injection, impressive efficacy with a safety concern that appears to be manageable, and a price that's at least half the cost of the established prophylaxis regimen.

RedBloodCellsOnWhite_1200x675

Roche's Genentech Inc. won US FDA approval on Nov. 16 for its once-weekly injection Hemlibra as a prophylactic treatment for adult and pediatric patients who have hemophilia A with inhibitors, which could free patients from multiple weekly infusions.

And at a cost that's at least half of the current prophylaxis treatment with potentially better efficacy and a safety...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from New Products

More from Scrip